Parathyroid hormone-related peptide (1-36)

Drug Profile

Parathyroid hormone-related peptide (1-36)

Alternative Names: hPTHrP-(1-36); PTHrP-(1-36)

Latest Information Update: 20 Nov 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yale University
  • Developer Ostotrophin LLC; University of Pittsburgh; Yale University
  • Class
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malignant hypercalcaemia; Postmenopausal osteoporosis

Most Recent Events

  • 27 Jul 2006 No development reported - Clinical-Phase-Unknown for Postmenopausal osteoporosis in USA (SC)
  • 04 Mar 2003 A study has been added to the adverse events and Musculoskeletal and Women's Health therapeutic trials sections
  • 05 Feb 2003 Clinical trials in Postmenopausal osteoporosis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top